Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...

However, researchers at the Penn Ovarian Cancer Research Center at the University of Pennsylvania are studying a surprising ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...

At first, doctors told her she had low-grade serous ovarian cancer, but she later learned she had borderline ovarian tumors. Campbell pursued a second and third opinion, which is how she was able ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Despite declining incidence rates, ovarian cancer prognosis remains poor, with survival rates between 30% and 50%. Serous carcinomas are the most prevalent histological subtype, constituting 37.66 ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Dan Paterson, President and CEO of Verastem, Inc. (NASDAQ:VSTM), a clinical-stage biopharmaceutical company with a market capitalization of $273 million, recently sold 858 shares of the company's ...

The two oral drugs are pending approval together, and would be the first treatment for this type of ovarian cancer, according to Verastem’s chief executive officer. Recurrent low-grade serous ...